NCT05452304 - AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

November 14, 2024

Study Completion Date

November 27, 2024

Conditions

Healthy SubjectsCrohns Disease

Interventions

BIOLOGICAL

AZD7798

Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.

BIOLOGICAL

Placebo

Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.

Trial Locations (1)

Research Site, Harrow